Myasthenia Gravis

Businessman climbing steps to pluck a star from the sky

Biotech

Regeneron posts phase 3 win, advancing push to muscle in on gMG

Regeneron plans to file for FDA approval of its siRNA candidate in the increasingly competitive generalized myasthenia gravis market.

Nick Paul Taylor Aug 26, 2025 9:41am

Graphic image of an arrow nailing the bullseye of a target

AstraZeneca's blockbuster contender hits phase 3 gMG goals

Jul 24, 2025 6:20am

A one dollar bill sitting next to a declining stock graph

Fierce Pharma

Vor Bio's surprise $4B revival deal splits investor reactions

Jun 26, 2025 10:55am

A photo finish at a horse race with both horses crossing the finish line

J&J links FcRn blocker to sustained benefits as FDA ruling nears

Apr 8, 2025 10:21am

relay

Immunovant posts phase 3 autoimmune win but won't seek approval

Mar 19, 2025 9:15am

JNJ

J&J posts adolescent myasthenia gravis data on $6B FcRn blocker

Oct 15, 2024 9:25am